Congress just returned to Washington, but there have been several 340B developments both in D.C. and in the states during the long summer recess. In my latest monthly column, I cover a few of these topics: 1) HRSA Solicits Bids … [Read more...]
News & Commentary
Key Takeaways from the 340B Coalition Summer Conference
August 8, 2019 by
The 340B Coalition, the umbrella group for the 13 national trade associations that represent the providers participating in the 340B drug discount program, held its annual meeting July 15-17 in Washington, D.C. In this month’s column, I will share … [Read more...]
Hospital specialty pharmacies offer a solution to growing problems: medication access & affordability
August 8, 2019 by
Over the past year, I have learned a lot about specialty pharmacy and its importance to 340B providers and patients. A staggering 65% of the new drugs that came to market in 2018 were specialty drugs. These therapies can improve care and … [Read more...]
President’s Proposal to Require Drug Manufacturers to Disclose Prices in TV Ads
August 7, 2019 by
Ted Slafsky of Wexford Solutions Is Interviewed by Fox News Radio's daily podcast on the President's Proposal to Require Drug Manufacturers to Disclose Prices in TV Ads … [Read more...]
The View From the Nation’s Capital
July 1, 2019 by
This month’s column covers: 1) the significant uptick in drug manufacturer notices of overcharges to 340B providers and the importance of monitoring these developments. (2) The untold story of a little-known individual who played a … [Read more...]
A Welcome Addition to the 340B Debate
May 29, 2019 by
The pharmaceutical industry has successfully harnessed the power of patient groups to help in their advocacy efforts throughout state capitals and in Washington, D.C. According to the most recent data available, drug companies and their trade groups … [Read more...]
Op-Ed in USA Today
May 3, 2019 by
I wanted to pass along an op-ed that I wrote for USA Today. The piece, which was published this week, focuses on how rural health care would suffer if the Affordable Care Act is repealed. In particular, I write about how the ACA … [Read more...]
The View from Washington, D.C.
April 1, 2019 by
Clearing Off The Desk...... In my latest column, I am going to tackle a few issues that are timely and relevant to 340B stakeholders. Sometimes, I will take a deep dive into a particular subject, but there is so much going on right now with 340B, … [Read more...]
Be Vigilant on State 340B Activity
March 14, 2019 by
For the last two years, the 340B program has come under unprecedented scrutiny from the Trump Administration and Congress. In the prior congressional session, several studies were conducted by federal and congressional watchdogs, five hearings were … [Read more...]
Will prescription drugs get cheaper this year? An expert rates the odds.
January 7, 2019 by
Will prescription drugs get cheaper this year? An expert rates the odds. This article first appeared in USA Today on January 7, 2019 Ted Slafsky, Opinion contributor As a 25-year veteran of the drug-pricing battle on Capitol Hill, I’m … [Read more...]